Novartis reported first-quarter revenue of $13.11 billion [2], missing analyst expectations of $13.56 billion [6].

This shortfall suggests a temporary dip in performance for the pharmaceutical giant, though the company continues to maintain its long-term growth trajectory. It highlights the ongoing tension between immediate quarterly results and the long-term strategic goals of the pharmaceutical industry.

According to reports, the company's core earnings per share (EPS) fell to $1.99 [3]. This represents a decline of 15% in constant currency (CC) and 13% in U.S. dollars [3]. Wall Street analysts had expected an average of $2.11 per share [1], meaning the company missed consensus by $0.08 [3].

Net sales for the quarter saw a decline of 1% year-over-year [4]. When measured in constant currency, the decline was 5% [4]. These figures indicate a slight contraction in the company's top-line growth during the first three months of the year.

Despite these misses, Novartis stated that the company delivered strong growth in priority brands and launches in Q1 [7]. The company also reaffirmed its fiscal year 2026 guidance [7].

Novartis continues to focus on its priority brands to drive future revenue. The company's commitment to its 2026 outlook remains a steadying factor for investors who may be concerned by the quarterly miss.

“Novartis reported first-quarter revenue of $13.11 billion, missing analyst expectations of $13.56 billion.”

The discrepancy between the current quarterly miss and the reaffirmed 2026 guidance suggests Novartis is prioritizing long-term strategic investment over short-term quarterly gains. By maintaining its 2026 targets, the company is signaling to the market that the current dip in revenue and net sales is a temporary temporary setback rather than a structural failure in its portfolio of priority brands.